What is a commonly used intravenous (IV) induction agent and its three associated side effects for a patient requiring anesthesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 21, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Propofol for IV Induction: Three Key Side Effects

Propofol is the recommended primary agent for intravenous induction of anesthesia, with three major side effects: hypotension (20-30% decrease in systolic/diastolic blood pressure), respiratory depression including apnea (occurring in 15.4% of patients), and pain on injection (affecting up to 30% of patients). 1, 2, 3

Why Propofol is the Preferred Choice

The American Society of Anesthesiologists specifically recommends propofol as the primary agent for intravenous induction, administered at 2 mg/kg for standard patients 1. This recommendation is based on propofol's rapid onset (30-45 seconds), predictable effects, and rapid recovery profile that distinguishes it from traditional anesthetic regimens 3, 4.

The Three Major Side Effects

1. Cardiovascular Depression (Hypotension)

Propofol causes dose-dependent myocardial depression and vasodilation, resulting in approximately 20-30% decreases in both systolic and diastolic blood pressure with minimal change in heart rate 2, 5. This effect occurs through:

  • Decreased cardiac output 2
  • Decreased systemic vascular resistance 2
  • Decreased arterial pressure 3

Critical management: Have vasopressors immediately available (ephedrine or metaraminol) before induction 3. This hypotensive effect is particularly pronounced in volume-depleted patients and those with cardiac disease 6, 2.

2. Respiratory Depression and Apnea

Propofol temporarily depresses respiration, with apnea occurring in 15.4% of patients following intravenous administration 7. Additional respiratory effects include:

  • Decreased tidal volume and respiratory rate (23.3% of IV patients) 7
  • Depression of ventilatory response to carbon dioxide for 15 minutes or more 7
  • Higher risk when combined with other CNS depressants, particularly opioids 7

The majority of serious adverse effects involving oxygenation and ventilation occur when midazolam or other sedatives are combined with medications capable of depressing the central nervous system 7. The incidence is particularly elevated in procedures involving the airway without endotracheal tube protection 2.

3. Pain on Injection

Pain during injection occurs in up to 30% of patients receiving intravenous bolus of propofol 3. This remains a persistent problem even with the newer emulsion formulations 8. Additional injection site reactions include:

  • Tenderness (5.6% of patients) 7
  • Redness (2.6% of patients) 7
  • Phlebitis (0.4% of patients) 7

Dosing Adjustments to Minimize Side Effects

Standard dosing: 2 mg/kg for healthy patients, administered slowly at approximately 20 mg every 10 seconds 1.

Reduced dosing: 0.5-1.5 mg/kg for elderly, debilitated, or ASA III-IV patients using slow administration 1. The elderly demonstrate marked sensitivity to propofol's cardiovascular effects, requiring closer monitoring for hypotension 9.

Common Pitfalls to Avoid

  • Never use propofol in patients with egg, soy, or sulfite allergies (contains 10% soybean oil and 1.2% purified egg phosphatide) 3
  • Avoid bolus dosing during maintenance to prevent hemodynamic instability 9
  • Do not use in volume-depleted patients without adequate resuscitation as hypotension will be exacerbated 6
  • Exercise extreme caution when combining with opioids or other CNS depressants due to synergistic respiratory depression 7, 2

Comparative Context

While propofol causes more cardiovascular depression than etomidate (which has minimal effects on cardiovascular regulation) 2, it offers significant advantages including reduced postoperative nausea and vomiting compared to volatile anesthetics 2, 9. In pediatric comparisons, propofol caused a mean 25% decrease in systolic blood pressure versus 15% with midazolam 7.

References

Guideline

Anesthesia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Propofol Infusion in Neurosurgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical pharmacology of propofol: an intravenous anesthetic agent.

DICP : the annals of pharmacotherapy, 1989

Research

Propofol: therapeutic indications and side-effects.

Current pharmaceutical design, 2004

Research

Propofol, the newest induction agent of anesthesia.

International journal of clinical pharmacology, therapy, and toxicology, 1988

Guideline

Guidelines for Total Intravenous Anesthesia (TIVA) with Target-Controlled Infusion (TCI)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.